StockNews.com assumed coverage on shares of Avinger (NASDAQ:AVGR – Free Report) in a research note released on Wednesday. The firm issued a hold rating on the medical device company’s stock.
Separately, HC Wainwright reiterated a buy rating and set a $5.00 target price on shares of Avinger in a research report on Thursday, March 21st.
Check Out Our Latest Report on Avinger
Avinger Stock Down 5.1 %
Avinger (NASDAQ:AVGR – Get Free Report) last issued its quarterly earnings results on Wednesday, March 20th. The medical device company reported ($3.93) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.64 by ($4.57). The company had revenue of $1.91 million during the quarter, compared to analysts’ expectations of $2.52 million. Analysts expect that Avinger will post -2.08 earnings per share for the current fiscal year.
Avinger Company Profile
Avinger, Inc, a commercial-stage medical device company, designs, manufactures, and sells a suite of image-guided and catheter-based systems used by physicians to treat patients with peripheral artery disease (PAD) primarily in the United States and Germany. The company develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures.
Featured Stories
- Five stocks we like better than Avinger
- Stock Market Holidays 2022-2025 – Here’s When the NYSE and NASDAQ Will be Closed
- 3 Stocks Leading the U.S. Agriculture Comeback
- Want to Profit on the Downtrend? Downtrends, Explained.
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What is a Bond Market Holiday? How to Invest and Trade
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Avinger Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avinger and related companies with MarketBeat.com's FREE daily email newsletter.